Aksigen Hospital Care

What Aksigen Hospital Care does

Aksigen Hospital Care (AHC) is a privately held, research-driven pharmaceutical company headquartered in Mumbai, India, founded in 1994 with a mission to introduce pathbreaking therapies in the anti-inflammatory space. The company pioneered systemic enzyme therapy in India and was the first Indian firm to launch the combination of Trypsin, Bromelain & Rutoside (TBR) for anti-inflammatory use, also developing the first and only dispersible formulation of TBR in the world. AHC received DCGI approval for the TBR combination after conducting a clinical trial in 300+ patients to establish safety and efficacy, and later extended the franchise into bone and joint disorder management. Its product portfolio centers on Elastros Pack (a combination of Minerals, Vitamins and amino acids for skeletal muscle cramp relief) and TBR-based therapies, serving Orthopaedic, Plastic surgery, and General surgery therapeutic areas.

The company operates a WHO GMP compliant manufacturing facility at MIDC, Ambarnath, dedicated to tablets and capsule formulations, and runs a PAN India sales and distribution operation that covers more than 100,000 retail outlets through a professional field sales team and direct engagement with healthcare institutions. AHC generates revenue primarily through domestic pharmaceutical product sales (one-time license-style transactions through retail distribution), supplemented by regional contract manufacturing services and technology transfer/licensing arrangements that it is actively pursuing for select overseas markets. Customer engagement is concentrated on orthopaedic practitioners, plastic surgeons, and general surgeons, with end-use patients (particularly those with skeletal muscle cramps) constituting the downstream consumer base.

The company is privately held with no disclosed parent company, no public funding rounds, and no institutional investor involvement visible in the source material. Strategic posture is consistent with a niche specialty pharmaceutical operator: focused portfolio, regulatory first-mover status in TBR, proprietary novel formulation technology, broad retail distribution, and selective openness to in-licensing and overseas contract manufacturing as alternative growth vectors.

Name

Aksigen Hospital Care

Legal name

AKSIGEN Hospital Care

Website

https://aksigen.com

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

251–500 employees

Short description

Aksigen Hospital Care is a privately held Indian pharmaceutical company founded in 1994 that develops and markets anti-inflammatory systemic enzyme therapies (Trypsin, Bromelain & Rutoside combinations) and muscle cramp relief products for Orthopaedic, Plastic surgery, and General surgery specialists across PAN India.

Ownership category

akta.pro rank

Product category

Anti-inflammatory Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (423450)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

Keywords

• Pharmaceutical manufacturing
• Anti-inflammatory therapy
• Systemic enzyme therapy
• Musculoskeletal pharmaceuticals
• Generic drug formulations

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Product Sales (Domestic): Revenue generated from sale of proprietary pharmaceutical products including Elastros (muscle cramp relief) and TBR-based therapies through domestic distribution network covering 100,000+ retail outlets across India.
2. Contract Manufacturing: Regional contract manufacturing services for select countries as an alternative business model to expand overseas presence.
3. Technology Transfer: Technology transfer arrangements for expediting availability of products in select countries through partnerships and licensing arrangements.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

Core offering

Aksigen Hospital Care manufactures and markets proprietary pharmaceutical formulations, primarily anti-inflammatory systemic enzyme therapies based on the Trypsin, Bromelain & Rutoside (TBR) combination and the Elastros Pack (minerals, vitamins and amino acids) for skeletal muscle cramp relief. Products are produced at a WHO GMP compliant facility in MIDC, Ambarnath and sold domestically through a professional sales team reaching 100,000+ retail outlets, targeting prescribers in orthopaedics, plastic surgery and general surgery.

Product overview

Aksigen Hospital Care is a pharmaceutical company offering a focused portfolio of drug therapies primarily in the anti-inflammatory and musculoskeletal space. The core product is Elastros Pack, a combination of Minerals, Vitamins, and amino acids for treating skeletal muscle cramps. Additionally, the company pioneered systemic enzyme therapy in India with its TBR (Trypsin, Bromelain & Rutoside) combination, including a novel dispersible formulation. The portfolio serves therapeutic areas including Orthopaedics, Plastic surgery, and General surgery.

Differentiator

Problem solved

Functional benefit

Products and services

• Elastros Pack

Quantifiable outcome

• Established safety and efficacy through clinical trial in 300+ patients for DCGI approval

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core and minor.

• In-licensing Partners (unnamed)coreStrategic or Co-development PartnerAHC seeks opportunities to in-license new products and technologies that fit with their development strategy and therapeutic areas of focus (Orthopaedics, Plastic surgery, General surgery). The company supports development of long-term alliances to create synergistic value through collaboration and flexibility.
• Regional Contract Manufacturing Partners (unnamed)minorOEM/ Whitelabel/ Licensing PartnerAHC is open to exploring alternative business models including regional contract manufacturing for expediting availability of its products in select countries. Also open to technology transfers.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Ajanta Pharma: Mid-to-large Indian specialty pharmaceutical company with branded formulations in multiple therapeutic specialties including pain management; overlapping therapeutic and distribution profile.
• Alkem Laboratories: Large Indian pharmaceutical company with broad branded specialty portfolio overlapping AHC's anti-inflammatory and surgical care therapeutic areas; competes in the same India hospital-channel segment.
• Torrent Pharmaceuticals: Large Indian pharmaceutical company with branded specialty franchise in pain, inflammation, and orthopaedic segments; comparable therapeutic overlap with AHC's core products.
• Mankind Pharma: One of India's largest domestic pharmaceutical companies with deep pan-India retail distribution; competes with AHC in the same retail channels and many of AHC's therapeutic categories.
• Cipla: India's largest pharmaceutical companies by revenue, with a broad branded specialty portfolio that includes anti-inflammatory and surgical-care products overlapping AHC's therapeutic areas.

Direct peers

• Unichem Laboratories: Indian specialty pharmaceutical manufacturer with branded formulations in musculoskeletal, anti-inflammatory, and pain segments; similar mid-sized niche pharma profile to AHC.
• TTK Healthcare: Indian healthcare and pharmaceutical group with a focused branded pharma portfolio, including orthopaedic and surgical-adjacent therapeutic areas; comparable niche-branded positioning to AHC.
• Modi Mundipharma: India-based specialty pharma with branded pain and anti-inflammatory portfolio serving orthopaedic and surgical specialties, directly comparable to AHC's therapeutic focus and India-centric distribution model.
• Troikaa Pharmaceuticals: Indian specialty pharmaceutical company focused on branded formulations in pain management and post-surgical care; comparable to AHC's niche branded approach in anti-inflammatory and surgical therapeutics.

Regional players

• Zuventus Healthcare (Emami Group): India-focused mid-sized branded pharma with presence in orthopaedic and pain management segments; comparable niche-branded positioning in the same Indian market as AHC.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/aksigen-hospital-care

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aksigen Hospital Care